Statins and chronic heart failure: do we need a large-scale outcome trial?

1994, Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, Lancet, 344, 1383 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 1999, Effect of metoprolol CR/XL in chronic heart failure, Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 Packer, 2001, Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, 1651, 10.1056/NEJM200105313442201 Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3 Cohn, 2000, Baseline demographics of the Valsartan Heart Failure Trial, Eur J Heart Failure, 2, 439, 10.1016/S1388-9842(00)00130-6 Swedberg, 1999, Candesartan in Heart failure-Assessment of reduction in Mortality and morbidity (CHARM), J Card Fail, 5, 276, 10.1016/S1071-9164(99)90013-1 Packer, 2002 Packer, 2002 Fox, 2001, Coronary artery disease as the cause of incident heart failure in the population, Eur Heart J, 22, 228, 10.1053/euhj.2000.2289 Yusuf, 1992, Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions, Lancet, 340, 1173, 10.1016/0140-6736(92)92889-N Kjekshus, 1997, The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease, J Card Fail, 3, 249, 10.1016/S1071-9164(97)90022-1 Cleland, 1999, Sudden death in heart failure, Eur J Heart Fail, 1, 41, 10.1016/S1388-9842(99)00009-4 Uretsky, 2000, Acute coronary findings at autopsy in heart failure patients with sudden death, Circulation, 102, 611, 10.1161/01.CIR.102.6.611 Cleland, 2001, Eur Heart J, 22, 1601, 10.1053/euhj.2000.2570 Wang, 1998, Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction, Am J Cardiol, 81, 531, 10.1016/S0002-9149(97)00974-0 van Boven, 1996, Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris, Circulation, 94, 1503, 10.1161/01.CIR.94.7.1503 Rahimtoola, 1995, From coronary artery disease to heart failure, Am J Cardiol, 75, 16E, 10.1016/S0002-9149(99)80443-3 O’Driscoll, 1997, Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month, Circulation, 95, 1126, 10.1161/01.CIR.95.5.1126 Rosenson, 1998, Antiatherothrombotic properties of statins, JAMA, 279, 1643, 10.1001/jama.279.20.1643 Lars Bastiaanse, 1994, The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes, Arch Biochem Biophys, 313, 58, 10.1006/abbi.1994.1358 Kureishi, 2000, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat Med, 6, 1004, 10.1038/79510 Strehlow, 2000, Angiotensin AT1receptor over-expression in hypercholesterolaemia, Ann Med, 32, 386, 10.3109/07853890008995944 Floras, 1993, Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure, J Am Coll Cardiol, 4, 72A, 10.1016/0735-1097(93)90466-E Pellizzer, 1999, Reduced dietary fat intake increases parasympathetic activity in healthy premenopausal women, Clin Exp Pharmacol Physiol, 26, 656, 10.1046/j.1440-1681.1999.03103.x Pehlivanidis, 2001, Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease, Atherosclerosis, 157, 463, 10.1016/S0021-9150(00)00746-2 Pliquett, 2001, Statins, J Card Fail, 7, 16 Torre-Amione, 1999, An overview of tumor necrosis factor alpha and the failing human heart, Curr Opin Cardiol, 14, 206, 10.1097/00001573-199905000-00003 Rosnenson, 1999, Inhibition of proinflammatory cytokine production by pravastatin, Lancet, 353, 983, 10.1016/S0140-6736(98)05917-0 Grip, 2000, Pravastatin down-regulates inflammatory mediators in human monocytes in vitro, Eur J Pharmacol, 410, 83, 10.1016/S0014-2999(00)00870-0 Hayashidani, 2002, Fluvastatin, a 3-hydroxy-3 methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction, Circulation, 105, 868, 10.1161/hc0702.104164 Bauersachs, 2001, Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction, Circulation, 104, 982, 10.1161/hc3401.095946 Luo, 1999, Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis, Clin Exp Pharmacol Physiol, 26, 903, 10.1046/j.1440-1681.1999.03165.x Oi, 1999, Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells, Eur J Pharmacol, 376, 139, 10.1016/S0014-2999(99)00282-4 Dechend, 2001, Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, Circulation, 104, 576, 10.1161/hc3001.092039 Segal, 2000, Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure, Eur J Heart Failure, 2, 96, 10.1016/S1388-9842(00)80342-6 de Lorgeril, 1999, Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients, J Cardiovasc Pharmacol, 33, 473, 10.1097/00005344-199903000-00018 Louis, 2002, Clinical trials update, Eur J Heart Failure, 4, 111, 10.1016/S1388-9842(01)00240-9 Vredevoe, 1998, Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy, Am J Cardiol, 82, 323, 10.1016/S0002-9149(98)00334-8 Rauchhaus, 2001, Serum total cholesterol, high density lipoprotein and prognosis in patients with chronic heart failure, J Am Coll Cardiol, 37, 156A Horwich, 2002, Low serum total cholesterol is associated with a marked increase in mortality in advanced heart failure, J Am Coll Cardiol, 39, 194A, 10.1016/S0735-1097(02)80863-4 Mehra, 2001, Does HDL-cholesterol level predict clinical outcome in advanced heart failure?, J Heart Lung Transplant, 20, 165, 10.1016/S1053-2498(00)00301-6 Mortensen, 1997, Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors, Mol Aspects Med, 18, S137, 10.1016/S0098-2997(97)00014-9 McMurray, 1993, Evidence of oxidative stress in chronic heart failure in humans, Eur Heart J, 14, 1493, 10.1093/eurheartj/14.11.1493 Katta, 2000, The effect of coenzyme Q10 in patients with congestive heart failure, Ann Intern Med, 132, 636, 10.7326/0003-4819-132-8-200004180-00006 Watson, 1999, Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure, J Am Coll Cardiol, 33, 1549, 10.1016/S0735-1097(99)00064-9 Hofman-Bang, 1995, Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure, J Card Fail, 1, 101, 10.1016/1071-9164(95)90011-X Langsjoen, 1985, Response of patients in classes III and IV of cardiomyopathy to therapy in blind and crossover trial with coenzyme Q10, Proc Natl Acad Sci U S A, 82, 4240, 10.1073/pnas.82.12.4240 Morisco, 1993, Effect of coenzyme Q10 therapy in patients with congestive heart failure, Clin Invest, 71, S134 Langsjoen, 1990, Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy, Am J Cardiol, 65, 521, 10.1016/0002-9149(90)90824-K Rueckschloss, 2001, Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells, Circulation, 104, 1767, 10.1161/hc4001.097056 Rauchhaus, 2000, The endotoxin-lipoprotein hypothesis, Lancet, 356, 930, 10.1016/S0140-6736(00)02690-8 Rauchhaus, 2000, Plasma cytokine parameters and mortality in patients with chronic heart failure, Circulation, 102, 3060, 10.1161/01.CIR.102.25.3060 Niebauer, 1999, Endotoxin and immune activation in chronic heart failure, Lancet, 353, 1838, 10.1016/S0140-6736(98)09286-1 2001, A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure, N Engl J Med, 344, 1659, 10.1056/NEJM200105313442202